This current study analysed the effects of EGFR inhibitor cetuximab on the activation of MAPK/ERK signalling, which is known to play a role in HNSCC tumorigenesis and treatment resistance development. This evidence concerns the gene MAPK1 and head and neck squamous cell carcinoma.